211 related articles for article (PubMed ID: 34691076)
1. Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.
Guo M; Qi F; Rao Q; Sun J; Du X; Qi Z; Yang B; Xia J
Front Immunol; 2021; 12():754961. PubMed ID: 34691076
[TBL] [Abstract][Full Text] [Related]
2. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
[TBL] [Abstract][Full Text] [Related]
3. The elevated expression of serum glutathione reductase in hepatocellular carcinoma and its role in assessing the therapeutic efficacy and prognosis of transarterial chemoembolization.
Zheng Q; Xu X; Weng J; Li M; Li B; Cao Y
Free Radic Biol Med; 2024 Aug; 221():225-234. PubMed ID: 38815771
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
[TBL] [Abstract][Full Text] [Related]
5. Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies.
Wirtz TH; Loosen SH; Schulze-Hagen M; Gorgulho J; Kandler J; Joerdens M; Demir M; Mohr R; Bruners P; Kuhl C; Trautwein C; Berres ML; Tacke F; Luedde T; Roderburg C
Clin Transl Sci; 2021 Sep; 14(5):1853-1863. PubMed ID: 33787014
[TBL] [Abstract][Full Text] [Related]
6. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization.
Wu YQ; Fan WZ; Xue M; Guo J; Wei JL; Wang Y; Yao W; Zhao Y; Li JP
Clin Transl Oncol; 2020 Jan; 22(1):70-80. PubMed ID: 31183764
[TBL] [Abstract][Full Text] [Related]
7. Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma.
Wang SY; Su TH; Chen BB; Liu CJ; Liu CH; Yang HC; Tseng TC; Chen PJ; Kao JH
J Formos Med Assoc; 2022 Aug; 121(8):1579-1587. PubMed ID: 35078686
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy.
Kohles N; Nagel D; Jüngst D; Durner J; Stieber P; Holdenrieder S
Tumour Biol; 2012 Feb; 33(1):33-40. PubMed ID: 21931992
[TBL] [Abstract][Full Text] [Related]
9. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization.
Kim SS; Cho HJ; Won JH; Bae JI; Kang DR; Lee JD; Shin SJ; Lee KM; Yoo BM; Kim JK; Lee JH; Ahn SJ; Park JH; Cho SW; Cheong JY
Cytokine; 2015 Dec; 76(2):449-457. PubMed ID: 26163999
[TBL] [Abstract][Full Text] [Related]
11. Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients.
Tang T; Qiu JL; Li GW; Huang MP; Li Y; Li YJ; Gu SZ
Clin Radiol; 2018 Mar; 73(3):259-265. PubMed ID: 29032942
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
13. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival.
Liu M; Liu J; Wang L; Wu H; Zhou C; Zhu H; Xu N; Xie Y
PLoS One; 2014; 9(10):e109347. PubMed ID: 25275448
[TBL] [Abstract][Full Text] [Related]
14. Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles.
Ren Z; Yue Y; Zhang Y; Dong J; Liu Y; Yang X; Lin X; Zhao X; Wei Z; Zheng Y; Wang T
Front Immunol; 2021; 12():624789. PubMed ID: 33717135
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
16. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization.
Ke Q; Xiang F; Xiao C; Huang Q; Liu X; Zeng Y; Wang L; Liu J
BMC Cancer; 2021 Oct; 21(1):1117. PubMed ID: 34663242
[TBL] [Abstract][Full Text] [Related]
17. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients.
Shim JH; Park JW; Kim JH; An M; Kong SY; Nam BH; Choi JI; Kim HB; Lee WJ; Kim CM
Cancer Sci; 2008 Oct; 99(10):2037-44. PubMed ID: 19016764
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study.
Sacco R; Bertini M; Petruzzi P; Bertoni M; Bargellini I; Bresci G; Federici G; Gambardella L; Metrangolo S; Parisi G; Romano A; Scaramuzzino A; Tumino E; Silvestri A; Altomare E; Vignali C; Capria A
World J Gastroenterol; 2009 Apr; 15(15):1843-8. PubMed ID: 19370781
[TBL] [Abstract][Full Text] [Related]
19. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization.
Ali HEA; Emam AA; Zeeneldin AA; Srour R; Tabashy R; El-Desouky ED; Abd Elmageed ZY; Abdel-Wahab AA
Clin Biochem; 2019 Mar; 65():45-52. PubMed ID: 30653948
[TBL] [Abstract][Full Text] [Related]
20. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
Zhao SM; Qiu LW; Zhao H; Gu WW; Yang XH; Gu ZX; Shi RF; Ni CF
J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
